Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone (PRNewswire) - Dec 13, 2022 - P1 | N=47 | NCT05256108 | Sponsor: Tris Pharma, Inc. | "Tris Pharma, Inc...announced new clinical data from its oral human abuse potential study in patients who are nondependent recreational opioid users, which demonstrate that cebranopadol (TRN-228) possesses significantly less likeability at high doses, above the therapeutic range versus immediate release (IR) formulations of tramadol or oxycodone. These data suggest that cebranopadol has a lower potential for abuse versus both C-II and C-IV opioids....Topline results show that one 600 µg dose of cebranopadol was similarly liked as placebo. Both 600 µg and 1000 µg doses of cebranopadol were liked significantly less than tramadol 600mg (17.34, p< 0.0001 and 7.77, p=0.0077, respectively) and oxycodone 40mg (24.43, p< 0.0001 and 14.86, p< 0.0001, respectively), suggesting cebranopadol has significantly less potential for abuse compared to both schedule II and schedule IV opioids."
P1 data • Back Pain • CNS Disorders • Immunology • Musculoskeletal Pain • Neuralgia • Pain
|